As someone who watched people from afar try to scale the mRNA vaccine process, the limiting factor was not manufacture of the RNA (BioNTech), but incorporation into lipid nanoparticles. That is not BioNTech's business (they are a subsidiary manufacturer for Pfizer)... it also is not Moderna's business since they outsource, but at least they are a direct source of funding rather than a cost center.

Money was not an object to scaling the manufacture of the vaccines. It was people, knowledge, and equipment that had to be designed, built and tested. That all happened in parallel with statistical evaluation and approval processes.

Nine people can't make a baby in 1 month no matter how much you pay them.

https://www.pfizer.com/news/press-release/press-release-deta...